Table 3.
ECOG performance status and life expectancy (according to treating physician's opinion) in patients with bone metastases/lesions: data from the detailed questionnaire
| Total (N = 8768) | France (n = 1665) | Germany (n = 2326) | Italy (n = 1680) | Spain (n = 1534) | UK (n = 1563) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST | HM | ST | HM | ST | HM | ST | HM | ST | HM | ST | HM | |
| Performance status (%) | ||||||||||||
| ECOG 0 | 16 | 31 | 16 | 38 | 9 | 9 | 25 | 42 | 18 | 20 | 15 | 40 |
| ECOG 1 | 47 | 38 | 48 | 36 | 52 | 54 | 40 | 33 | 47 | 31 | 45 | 40 |
| ECOG 2 | 27 | 22 | 28 | 18 | 29 | 34 | 25 | 19 | 26 | 30 | 26 | 14 |
| ECOG 3 | 9 | 6 | 7 | 6 | 9 | 2 | 8 | 5 | 7 | 15 | 12 | 4 |
| ECOG 4 | 1 | 1 | 1 | 3 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 2 |
| Life expectancy (%) | ||||||||||||
| <1 year | 17 | 4 | 15 | 3 | 10 | 6 | 20 | 5 | 24 | 3 | 22 | 4 |
| 1–3 years | 46 | 34 | 42 | 25 | 43 | 41 | 47 | 33 | 48 | 50 | 53 | 26 |
| >3 years | 36 | 60 | 42 | 69 | 47 | 52 | 33 | 62 | 27 | 47 | 26 | 69 |
ECOG, Eastern Cooperative Oncology Group; HM, haematological malignancy; ST, solid tumour.